Avalyn Pharma Inc.
No SEC Form 4 filings for $AVLN in the last 30 days.
See all $AVLN insider activity →Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ck0001540171-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE (this “ Amendment ”) is made and entered into as of June 29, 2026 (the “ Effective Date ”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation
Over the past 7 days, alphai's AI scored 1 news story mentioning AVLN (Avalyn Pharma Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AVLN coverage spans market movers and corporate actions.
This reads more like a listing/positioning catalyst than a new fundamental datapoint, with limited incremental earnings or trial results detail.
The 8-K discloses a lease/sublease amendment with defined rent schedules and an expansion of subleased premises, which can affect near-term cash burn and operating costs.
alphai scores every news story that mentions AVLN with an AI model for sentiment and relevance, and aggregates insider trades from Avalyn Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.
7 min readAvalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ck0001540171-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE (this “ Amendment ”) is made and entered into as of June 29, 2026 (the “ Effective Date ”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation
4 min read